AstraZeneca, Ionis Pharmaceuticals get FDA approval of Wainua for ATTRv-PN

In a major development for hereditary transthyretin-mediated amyloidosis (ATTRv-PN or hATTR-PN) patients, the US Food and Drug Administration (FDA) has approved Wainua (eplontersen), developed by ... Read More